News

Standortmanagement Golm GmbH | Research innovations and knowledge transfer, new office and laboratory buildings for the settlement of further start-ups and companies. In the Potsdam Science Park, the community of locations is growing and with it the space for visions, collaboration and numerous new interfaces for knowledge and technology transfer.

In the Potsdam Science Park, the trains will run differently from December 11, 2022, and Deutsche Bahn will change its timetables. Commuters should note the new departure times and the changed route in the coming weeks. We have summarised the most important information for you here.

MPICI Biomaterials | Max Planck Director Prof. Dr. Peter Fratzl has been appointed honorary life member by the Chinese Chemical Society (CCS). The CCS describes this nomination as “the highest honor bestowed on the world’s most distinguished chemists and materials scientists”. Peter Fratzl is thus one of a total of 70 honorary members, 24 of…

MPIKG Biomolecular Systems | Dr. Martina Delbianco, group leader at the Max Planck Institute of Colloids and Interfaces, was selected to receive a grant of 1.5 million euros from the European Research Council (ERC). Over a period of five years, the EU will fund the development of programmable carbohydrate architectures, which in the long term…

With its unique number of scientific institutions, clinics, its broad infrastructure and the growing number of companies and start-ups, the region offers excellent conditions for innovation, growth and employment. A central factor for successful development is the close cooperation of all stakeholders and, in particular, the close networking of science and industry. Together with the…

Bayer AG | Monheim, Nov. 10, 2022 | Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix will continue its start-up approach as a standalone entity wholly-owned by Bayer